VICTORIA, BC / ACCESSWIRE / August 31, 2020 / IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV:IPA)(OTCQB:IPATF)(FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced today announced that CEO Jennifer Bath will present to investors attending the LD 500 investor conference on Friday, September 4, 2020 at 1:00pm EST. Dr. Bath will also host one-on-one investor meetings on September 2 and September 4.
“ImmunoPrecise has emerged as a leader in a US$40B therapeutic discovery market. Between our COVID-19 research, rapidly expanding pipeline, and our continuously growing pipeline of programs, we have many fantastic updates to share. We look forward to discussing these developments and more with investors attending the LD 500 conference.”
View Dr. Bath’s video presentation
To book a meeting, register here: https://ld-micro-conference.events.issuerdirect.com/.
“We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space,” said Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View ImmunoPrecise’s profile here: https://www.ldmicro.com/profile/IPA.V.
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming “500” in September is the Company’s most ambitious project yet, and the first event that is accessible to everyone.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact firstname.lastname@example.org.
For further information: For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: email@example.com, Contact Financial Corp., Suite 810, 609 Granville Street, P.O. Box 10322, Vancouver, B.C., V7Y 1G5, Canada.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend”, “should” and similar expressions to identify forward-looking statements and include the Company’s beliefs with respect to the potential for its antibodies to be further developed or approved to treat COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: ImmunoPrecise Antibodies Ltd. via LD Micro
View source version on accesswire.com: